RGD Reference Report - Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report.

Authors: Lee, Sanghoon  Day, Nancy S  Miles, Rodney R  Perkins, Sherrie L  Lim, Megan S  Ayello, Janet  van de Ven, Carmella  Harrison, Lauren  El-Mallawany, Nader K  Goldman, Stanton  Cairo, Mitchell S 
Citation: Lee S, etal., Br J Haematol. 2017 May;177(4):601-611. doi: 10.1111/bjh.14604. Epub 2017 May 4.
RGD ID: 124713565
Pubmed: PMID:28474336   (View Abstract at PubMed)
PMCID: PMC5435544   (View Article at PubMed Central)
DOI: DOI:10.1111/bjh.14604   (Journal Full-text)

Burkitt lymphoma (BL) is the most common histological subtype of non-Hodgkin lymphoma (NHL) in children and adolescents. Through the introduction of short intensive multi-agent chemoimmunotherapy, survival has improved significantly over the past 30 years. However, this successful approach is limited by significant chemotherapy-induced acute toxicity and risk of developing resistant disease, demonstrating the need to identify less toxic and targeted therapies. We analysed the comparative genomic signature and targetable signalling pathways in paediatric BL (PEBL) samples from the Children's Oncology Group study (ANHL01P1) by genomic profiling and selected genes were confirmed by quantitative real time polymerase chain reaction. These results were compared to PEBL samples from public databases and utilised the Gene Expression Omnibus (GEO) Series (GSE) 10172 and 4475 (n = 16), and 4732 (n = 15). Three hundred and seventy-six genes (approximately 25%) were similarly expressed among three PEBL sample groups. Several target genes in Toll-like receptor signalling, JAK-STAT signalling and MAPK signalling were significantly overexpressed in PEBL. In addition, several tyrosine kinases, including Bruton tyrosine kinase, protein tyrosine phosphatase and histone deacetylase inhibitor were highly expressed in PEBL. These pre-clinical results suggest that specific signal transduction pathways are overly expressed in PEBL and several pathways could serve as potential future therapeutic targets.



RGD Manual Disease Annotations    Click to see Annotation Detail View
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
BTKHumanBurkitt lymphoma treatmentHEP mRNA:increased expression:multiple (human)RGD 

Objects Annotated

Genes (Homo sapiens)
BTK  (Bruton tyrosine kinase)


Additional Information